Pellicular anion-exchange chromatography applied to RNAi assays for monitoring strand stoichiometry and RNA stability.

Mar 24 2011

Author: J. R. Thayer, Srinivasa Rao, Christopher Pohl (Dionex Corporation) Yansheng Wu, and Mark Angelino (Archemix Corporation). on behalf of Unassigned Independent Article

Free to read

This article has been unlocked and is ready to read.


RNAi products require both single strand and duplex impurity assays. Duplex assays should allow titration of guide or passenger strands that may be in excess. These assays are chromatographic, and typically employ two steps: First, as is  common to other single-stranded therapeutics, denaturing conditions must resolve both guide and passenger strand, and thus may reveal impurities formed during the annealing process. Next, native conditions, where the duplex is stable, are used to resolve the duplex and both single strands from one another.
This allows analysis of possible duplex impurities, such as those arising from annealed impurities from the guide, passenger, or both strands. RNAi component strands, or those of other therapeutic modes, may harbor one or two phosphorothioate linkages. These introduce diastereoisomers that may impact the RNAi stability or efficacy. Resolution of the diastereoisomers allows assessment of the influence of each in the process, and where the separation can be accomplished at mg levels, can support bioanalytical identification of the contribution of each diastereomer. We describe here simple anion-exchange chromatographic approaches to accomplish these separations.

Among the continually increasing numbers of RNA therapeutic modes, four have been identified as clinically promising. These are Antisense oligonucleotides (ONs) [1], Ribozymes [2], Aptamers [3], and RNA interference (RNAi ) [4,5] ONs. While several new non-coding RNA forms have been described recently, these four therapeutic modes show promise. The RNAi approach conscripts a subset of microRNA (miRNA) processing machinery, allowing exogenously supplied RNA of specific sequence to stimulate turnover of accordingly-specific mRNA [6]. Where the activity (or defect) in a specific protein is known to produce or support a disease state, turnover of the mRNA encoding that specific protein will suppress progression of that disease, or it symptoms.

Numerous examples of gene-product “Knock- Down” have been described, ranging from control of Cholesterol levels [7] to suppression of Ebola Virus replication [8]. Understandably, this has stimulated intense interest in RNAi as a new therapeutic model.

Free to read

This article has been unlocked and is ready to read.


Digital Edition

Chromatography Today - Buyers' Guide 2022

December 2021

In This Edition Modern & Practocal Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


ASMS Conference

Jun 04 2023 Houston, TX, USA

Plastics Recycling World Expo Europe

Jun 14 2023 Essen, Germany

HPLC 2023

Jun 18 2023 Dusseldorf, Germany


Jul 04 2023 Cardiff, UK

Water Expo Nigeria 2023

Jul 11 2023 Lagos, Nigeria

View all events